Sanara MedTech (SMTI) vs STAAR Surgical (STAA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sanara MedTech (SMTI) has outperformed STAAR Surgical (STAA) over the past year, gaining 8.4% versus a loss of 16.3%. Over five years, SMTI leads with a +6.3% price change compared with -80.5% for STAA. STAAR Surgical is the larger company by market cap ($1.08 billion vs $322.0 million), about 3.3 times the size.
On valuation, STAAR Surgical trades at a lower forward P/E (19.3x vs 64.9x for Sanara MedTech).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SMTI | STAA |
|---|---|---|
| Share price | $35.05 | $21.51 |
| Market cap | $322.04M | $1.08B |
| 1-day change | 0.00% | -3.91% |
| YTD return | +50.11% | -3.16% |
| 1-year return | +8.41% | -16.32% |
| 5-year return | +6.28% | -80.54% |
| P/E ratio (TTM) | — | 268.81 |
| Forward P/E | 64.91 | 19.35 |
| EPS (TTM) | $-0.04 | $0.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.34 | $35.87 |
| 52-week low | $16.05 | $15.59 |
| Distance from 52-week high | -0.82% | -40.05% |
| Analyst consensus | none | buy |
| Avg. price target upside | -0.14% | +30.20% |
| Average volume | 280.40K | 999.97K |
| Shares outstanding | 9.19M | 50.14M |
| Employees | 108 | 921 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STAAR Surgical is about 3.3 times larger than Sanara MedTech by market value ($1.08B vs $322.04M).
- SMTI has outperformed STAA by 24.7 percentage points over the past year.
About Sanara MedTech
SMTI stock →Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns.
Health Care · Industrial Specialties · 108 employees
About STAAR Surgical
STAA stock →STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Health Care · Ophthalmic Goods · 921 employees
SMTI vs STAA FAQ
Which is bigger, Sanara MedTech or STAAR Surgical?
STAAR Surgical (STAA) is larger, with a market capitalization of $1.08B compared with $322.04M for Sanara MedTech (SMTI).
Which stock has performed better over the past year, SMTI or STAA?
SMTI returned +8.41% over the past 12 months, compared with -16.32% for STAA (price return, excluding dividends). Past performance does not predict future results.
Are Sanara MedTech and STAAR Surgical in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Sanara MedTech and Ophthalmic Goods for STAAR Surgical.